The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer

Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

Yusuke Tomita, Min Jung Lee, Sunmin Lee, Saori Tomita, Saranya Chumsri, Scott Cruickshank, Peter Ordentlich, Jane B. Trepel

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a nonsteroidal aromatase inhibitor. ENCORE 301 showed an 8.3-mo improvement in median overall survival among patients who received entinostat. We investigated the impact of entinostat on immune subsets with CD40, HLA-DR, and immune checkpoint receptor expression analyses in 34 patient blood samples from ENCORE 301. We found that entinostat significantly decreased granulocytic and monocytic MDSCs at cycle 1 day 15. MDSC CD40 was significantly downregulated by entinostat. A significant increase in HLA-DR expression on CD14+ monocytes by entinostat was observed. Entinostat did not impact T-cell subsets or T-cell immune checkpoint receptor expression. Our findings suggest that a significant interplay between this epigenetic regimen and host immune homeostatic mechanisms may impact therapeutic outcome.

Original languageEnglish (US)
Article numbere1219008
JournalOncoImmunology
Volume5
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

exemestane
Epigenomics
Estrogen Receptors
Immunity
Placebos
Breast Neoplasms
HLA-DR Antigens
Therapeutics
Aromatase Inhibitors
Histone Deacetylase Inhibitors
entinostat
T-Lymphocyte Subsets

Keywords

  • Breast cancer
  • entinostat
  • exemestane
  • histone deacetylase inhibitors
  • HLA-DR
  • immune checkpoint receptor
  • immune subsets
  • monocyte
  • myeloid-derived suppressor cell
  • regulatory T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer : Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. / Tomita, Yusuke; Lee, Min Jung; Lee, Sunmin; Tomita, Saori; Chumsri, Saranya; Cruickshank, Scott; Ordentlich, Peter; Trepel, Jane B.

In: OncoImmunology, Vol. 5, No. 11, e1219008, 01.11.2016.

Research output: Contribution to journalArticle

@article{c1e735c6c77742b89e4914c49aa577f6,
title = "The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat",
abstract = "Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a nonsteroidal aromatase inhibitor. ENCORE 301 showed an 8.3-mo improvement in median overall survival among patients who received entinostat. We investigated the impact of entinostat on immune subsets with CD40, HLA-DR, and immune checkpoint receptor expression analyses in 34 patient blood samples from ENCORE 301. We found that entinostat significantly decreased granulocytic and monocytic MDSCs at cycle 1 day 15. MDSC CD40 was significantly downregulated by entinostat. A significant increase in HLA-DR expression on CD14+ monocytes by entinostat was observed. Entinostat did not impact T-cell subsets or T-cell immune checkpoint receptor expression. Our findings suggest that a significant interplay between this epigenetic regimen and host immune homeostatic mechanisms may impact therapeutic outcome.",
keywords = "Breast cancer, entinostat, exemestane, histone deacetylase inhibitors, HLA-DR, immune checkpoint receptor, immune subsets, monocyte, myeloid-derived suppressor cell, regulatory T cell",
author = "Yusuke Tomita and Lee, {Min Jung} and Sunmin Lee and Saori Tomita and Saranya Chumsri and Scott Cruickshank and Peter Ordentlich and Trepel, {Jane B.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/2162402X.2016.1219008",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer

T2 - Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

AU - Tomita, Yusuke

AU - Lee, Min Jung

AU - Lee, Sunmin

AU - Tomita, Saori

AU - Chumsri, Saranya

AU - Cruickshank, Scott

AU - Ordentlich, Peter

AU - Trepel, Jane B.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a nonsteroidal aromatase inhibitor. ENCORE 301 showed an 8.3-mo improvement in median overall survival among patients who received entinostat. We investigated the impact of entinostat on immune subsets with CD40, HLA-DR, and immune checkpoint receptor expression analyses in 34 patient blood samples from ENCORE 301. We found that entinostat significantly decreased granulocytic and monocytic MDSCs at cycle 1 day 15. MDSC CD40 was significantly downregulated by entinostat. A significant increase in HLA-DR expression on CD14+ monocytes by entinostat was observed. Entinostat did not impact T-cell subsets or T-cell immune checkpoint receptor expression. Our findings suggest that a significant interplay between this epigenetic regimen and host immune homeostatic mechanisms may impact therapeutic outcome.

AB - Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a nonsteroidal aromatase inhibitor. ENCORE 301 showed an 8.3-mo improvement in median overall survival among patients who received entinostat. We investigated the impact of entinostat on immune subsets with CD40, HLA-DR, and immune checkpoint receptor expression analyses in 34 patient blood samples from ENCORE 301. We found that entinostat significantly decreased granulocytic and monocytic MDSCs at cycle 1 day 15. MDSC CD40 was significantly downregulated by entinostat. A significant increase in HLA-DR expression on CD14+ monocytes by entinostat was observed. Entinostat did not impact T-cell subsets or T-cell immune checkpoint receptor expression. Our findings suggest that a significant interplay between this epigenetic regimen and host immune homeostatic mechanisms may impact therapeutic outcome.

KW - Breast cancer

KW - entinostat

KW - exemestane

KW - histone deacetylase inhibitors

KW - HLA-DR

KW - immune checkpoint receptor

KW - immune subsets

KW - monocyte

KW - myeloid-derived suppressor cell

KW - regulatory T cell

UR - http://www.scopus.com/inward/record.url?scp=84992529735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992529735&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1219008

DO - 10.1080/2162402X.2016.1219008

M3 - Article

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 11

M1 - e1219008

ER -